

**Comparative hydrodynamic and nanoscale imaging study on the interactions of teicoplanin-A2 and bovine submaxillary mucin as a model ocular mucin**

CHUN, Taewoo, PATTEM, Jacob, GILLIS, Richard <<http://orcid.org/0000-0002-7607-6808>>, DINU, Vlad T., YAKUBOV, Gleb E., CORFIELD, Anthony P. and HARDING, Stephen E.

Available from Sheffield Hallam University Research Archive (SHURA) at:

<https://shura.shu.ac.uk/32139/>

---

This document is the Supplemental Material

**Citation:**

CHUN, Taewoo, PATTEM, Jacob, GILLIS, Richard, DINU, Vlad T., YAKUBOV, Gleb E., CORFIELD, Anthony P. and HARDING, Stephen E. (2023). Comparative hydrodynamic and nanoscale imaging study on the interactions of teicoplanin-A2 and bovine submaxillary mucin as a model ocular mucin. *Scientific Reports*, 13 (1): 11367. [Article]

---

**Copyright and re-use policy**





See <http://shura.shu.ac.uk/information.html>

**Comparative hydrodynamic and nanoscale imaging study on the interactions of teicoplanin-A2 and bovine submaxillary mucin as a model ocular mucin  
(Chun et al)**





Supplementary Information for Figure 4: AFM imaging for teicoplanin-BSM mixtures, with controls

# Teicoplanin control 0.125 mg/ml – H<sub>2</sub>O





Area 1



Area 2





Area 3







# Teicoplanin Control 1.25 mg/ml – H<sub>2</sub>O



Area 1



Area 2







Area 3







# Teicoplanin Control 12.5 mg/ml – H<sub>2</sub>O





Area 1



Area 2




Area 3






# BSM Control 1 mg/ml – H<sub>2</sub>O


Area 1



Area 2




Area 3




# TP (0.125 mg/ml) - BSM (1 mg/ml) – H<sub>2</sub>O


Area 1



Area 2




Area 3






TP (1.25 mg/ml) - BSM (1 mg/ml) – H<sub>2</sub>O


Area 1



Area 2







Area 3









# TP (12.5 mg/ml) - BSM (1 mg/ml) – H<sub>2</sub>O

Area 1







Area 2







## Additional TP (12.5 mg/ml) - BSM (1 mg/ml) – H<sub>2</sub>O

Area 1



Area 2



Area 3

